Trial reportAnnals of surgical oncology2018
Phase 2 Open-Label Trial Investigating Percutaneous Laser Ablation for Treatment of Early-Stage Breast Cancer: MRI, Pathology, and Outcome Correlations.
Trial report in Annals of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Thermal ablation for early-stage breast cancer: cryoablation, microwave ablation, radiofrequency ablation, high-intensity focused ultrasound ablation, and laser ablation - a systematic review.Breast (Edinburgh, Scotland) · 2026Pooled it
- Percutaneous Management of Breast Cancer: a Systematic Review.Current oncology reports · 2022Pooled it
- Incorporating Percutaneous Laser Ablation for Early Breast Cancer Treatment: A Systematic Review.Technology in cancer research & treatmentPooled it
- Construction and Characterization of PDA@MnOPharmaceutics · 2025Article
- Advances in Second Near-Infrared Window Photothermal Agents and Photothermal Therapy for Tumors in Interdisciplinary Medical Research.Pharmaceutics · 2025Review
- Immunomodulatory effects of photothermal therapy in breast cancer: advances and challenges.Frontiers in immunology · 2025Review
- From Simulation to Surgery: Comprehensive Validation of an Optical Sensor for Monitoring Focal Laser Ablation of Solid Organ Tumors.IEEE sensors journal · 2024Article
- Nanotechnology Applications in Breast Cancer Immunotherapy.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Magnetic resonance imaging-guided radiofrequency ablation of breast cancer: a current state of the art review.Diagnostic and interventional radiology (Ankara, Turkey) · 2024Article
- Review
- Non-Surgical Definitive Treatment for Operable Breast Cancer: Current Status and Future Prospects.Cancers · 2023Review
- Potential and Progress of 2D Materials in Photomedicine for Cancer Treatment.ACS applied bio materials · 2023Review
- Interstitial Optical Monitoring of Focal Laser Ablation.IEEE transactions on bio-medical engineering · 2022Article
- Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer.Frontiers in immunology · 2022Review
- Article
- Clinical development and potential of photothermal and photodynamic therapies for cancer.Nature reviews. Clinical oncology · 2020Review
- Microwave Ablation Versus Nipple Sparing Mastectomy for Breast Cancer ≤5 cm: A Pilot Cohort Study.Frontiers in oncology · 2020Article
- Ablative Therapies for Breast Cancer: State of Art.Technology in cancer research & treatmentReview
- Agar-based Phantom for Evaluating Targeting of High-intensity Focused Ultrasound Systems for Breast Ablation.Journal of medical physicsArticle
Corrections and comments
- Erratum issued
Authors and funding
20 authors at 8 institutions in 2 countries.
Funding
Abstract
backgroundAn institutional review board-approved, multicenter clinical trial was designed to determine the efficacy and outcome of percutaneous laser ablation (PLA) in the treatment of invasive ductal breast carcinoma (IDC). Post-ablation magnetic resonance imaging (MRI) was compared with surgical pathology in evaluation of residual post-ablation IDC and ductal carcinoma in situ.
methodsPatients with a single focus of IDC 20 mm or smaller by pre-ablation MRI were treated with PLA. The patients underwent a 28-day post-ablation MRI, followed by surgical resection. Cell viability criteria were applied to pre- and post-ablation pathology specimens, which evaluated hematoxylin-eosin (H&E), cytokeratin (CK) 8/18, estrogen receptor, and Ki67 staining patterns.
resultsIn this study, 61 patients were reported as the intention-to-treat cohort for determination of PLA efficacy. Of these 61 patients, 51 (84%) had complete tumor ablation confirmed by pathology analysis. One subject's MRI imaging was not performed per protocol, which left 60 subjects evaluable for MRI pathology correlation. Five patients (8.3%) had residual IDC shown by both MRI and pathology. Post-ablation discordance was noted between MRI and pathology, with four patients (6.7%) false-positive and four patients (6.7%) false-negative. The negative predictive value (NPV) of MRI for all the patients was 92.2% (95% confidence interval [CI], 71.9-91.9%). Of the 47 patients (97.9%) with tumors 15 mm or smaller, 46 were completely ablated, with an MRI NPV of 97.7% (95% CI, 86.2-99.9%).
conclusionsPercutaneous laser ablation is a potential alternative to surgery for treatment of early-stage IDC. Strong correlations exist between post-ablation MRI and pathologic alterations in CK8/18, ER, and Ki67 staining.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.